Search

A recent report from the Korea Institute of Science and Technology discusses research findings on mecamylamine therapy for nicotine withdrawal. The study aimed to understand the features of early nicotine withdrawal and its potential for the prevention and treatment of drug addiction. The researchers conducted tests on mice and found that withdrawal-like signs could be precipitated by mecamylamine, a nicotinic antagonist, indicating a potential model of acute dependence on nicotine. The study concluded that early nicotine withdrawal primarily causes physical symptoms and does not affect cognitive functioning or social behavior. [Extracted from the article]

"In an embodiment, a method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient in need thereof is presented comprising: administering to the patient in need thereof a therapeutically effective amount of a composition comprising a nicotinic receptor antagonist; a peroxisome proliferator activated receptor gamma (PPAR-g) agonist; and a pharmaceutically acceptable carrier. "Given the lack of available treatments for COVID-19, what is needed is a composition that is efficacious as a treatment and/or preventative for infection by SARS-CoV-2 virus." The nicotinic receptor antagonist, mecamylamine or mecamylamine isomer, and the PPAR-g agonist, pioglitazone, act synergistically to reduce SARS-CoV-2 replication in virus-infected cells of the patient and also act synergistically to decrease inflammatory cytokine expression in the patient. [Extracted from the article]

Keywords: Antiadrenergic Agents; Antihypertensives; Biogenic Amines; Cardiovascular Agents; Catecholamines; Dopamine; Dopamine Hydrochloride; Drugs and Therapies; Ghrelin; Health and Medicine; Hormones; Mecamylamine Therapy; Organic Chemicals; Peptide Hormones; Peptide Proteins; Peripherally Acting; Pharmaceuticals EN Antiadrenergic Agents Antihypertensives Biogenic Amines Cardiovascular Agents Catecholamines Dopamine Dopamine Hydrochloride Drugs and Therapies Ghrelin Health and Medicine Hormones Mecamylamine Therapy Organic Chemicals Peptide Hormones Peptide Proteins Peripherally Acting Pharmaceuticals 1714 1714 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on mecamylamine therapy is now available. In our previous in vitro superfusion studies, it was demonstrated that ghrelin and nicotine stimulate equally the dopamine release in the rat amygdala, and ghrelin amplifies the nicotine-induced dopamine release in the rat striatum. [Extracted from the article]

Antiadrenergic Agents, Antihypertensives, Cardiovascular Agents, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Drugs and Therapies - Mecamylamine Therapy, Health and Medicine, Hospitals, Hydrocarbons, Mecamylamine, Mecamylamine Therapy, Monoterpenes, Organic Chemicals, Peripherally Acting, Pharmaceuticals, Terpenes, Norbornanes Study Drug Administration: During challenge drug study visits, participants will receive double-blinded administration of study drug (20 mg oral mecamylamine) or placebo. Keywords: Antiadrenergic Agents; Antihypertensives; Cardiovascular Agents; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Drugs and Therapies - Mecamylamine Therapy; Health and Medicine; Hospitals; Hydrocarbons; Mecamylamine; Mecamylamine Therapy; Monoterpenes; Norbornanes; Organic Chemicals; Peripherally Acting; Pharmaceuticals; Terpenes EN Antiadrenergic Agents Antihypertensives Cardiovascular Agents Clinical Research Clinical Trials and Studies Drugs and Therapies Drugs and Therapies - Mecamylamine Therapy Health and Medicine Hospitals Hydrocarbons Mecamylamine Mecamylamine Therapy Monoterpenes Norbornanes Organic Chemicals Peripherally Acting Pharmaceuticals Terpenes 545 545 1 09/04/23 20230904 NES 230904 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT06002477, which has the following summary description: "This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. [Extracted from the article]

Focuses on a study of the effects of the drug mecamylamine on memory as of May 1, 1999. Details of the experiment conducted by Jerry Buccafusco et al; Finding that, in small doses, the drug can improve memory, but in large doses, can impair it; Outlook for the drug's use as a treatment for Alzheimer's disease patients.

The article considers mecamylamine as a new treatment for macular edema, a diabetes-induced eye disease. It details the early-stage human experiments with mecamylamine led by the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Maryland and how participants in the study showed "significant improvement" in their overall vision. It reveals that CoMentis Inc. of South San Francisco, California developed mecamylamine, with funding from the Juvenile Diabetes Research Foundation.

The article discusses research being done on the use of mecamylamine and arbaclofen for gastrointestinal disorders. It references a study by AGI Therapeutics PLC published on February 1, 2007. Stool consistency was significantly improved in patients with functional diarrhoea, who were given once-daily mecamylamine for 12 weeks. There were significant improvements from baseline in severity of illness and in gastrointestinal symptoms in patients with functional dyspepsia, who were treated with arbaclofen.

The article discusses the findings of a multicenter study on the use of mecamylamine in treating mental depression. Using the Hamilton Depression Rating Scale and the Clinical Global Impression subscale of severity of illness, the study revealed that mecamylamine enhances the therapeutic effect of citalopram in patients with depression.